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DOI 10.1016/j.str.2011.02.013SUMMARY consists of three extracellular immunoglobulin domains, V, C1,Nonenzymatic protein glycation results in the forma-
tion of advanced glycation end products (AGEs) that
are implicated in the pathology of diabetes, chronic
inflammation, Alzheimer’s disease, and cancer.
AGEs mediate their effects primarily through
a receptor-dependent pathway in which AGEs bind
to a specific cell surface associated receptor, the
Receptor for AGEs (RAGE). N3-carboxy-methyl-
lysine (CML) and N3-carboxy-ethyl-lysine (CEL),
constitute two of the major AGE structures found in
tissue and blood plasma, and are physiological
ligands of RAGE. The solution structure of a CEL-
containing peptide-RAGE V domain complex reveals
that the carboxyethyl moiety fits inside a positively
charged cavity of the V domain. Peptide backbone
atoms make specific contacts with the V domain.
The geometry of the bound CEL peptide is compat-
ible with many CML (CEL)-modified sites found in
plasma proteins. The structure explains how such
patterned ligands as CML (CEL)-proteins bind to
RAGE and contribute to RAGE signaling.
INTRODUCTION
The products of nonenzymatic glycation and oxidation of
proteins, the early and the advanced glycation end products
(AGEs), are a heterogeneous class of compounds that form
under diverse circumstances in response to cellular stress
(Brownlee et al., 1984). Specific AGE compounds, namely
N3-carboxy-methyl-lysine (CML) and N3-carboxy-ethyl-lysine
(CEL) (Figure 1A), due to their interactions with the Receptor
for AGEs (RAGE), have been linked to complications of diabetes
and chronic inflammation, the severity of Alzheimer’s disease,
and cancer (Ishiguro et al., 2005; Ramasamy et al., 2005a,
2005b; Thornalley, 1999; Valente et al., 2010). RAGE is located
in the major histocompatibility complex class III (MHC III) region
suggesting its involvement in immune responses (Schmidt and
Stern, 2001; Sugaya et al., 1994). RAGE is a member of the
immunoglobulin superfamily of cell surface molecules and722 Structure 19, 722–732, May 11, 2011 ª2011 Elsevier Ltd All rightand C2, a transmembrane helix and a short cytosolic tail (Hori
et al., 1995; Neeper et al., 1992). In spite of their structural diver-
sity, AGEs bind only to the V domain of RAGE (Kislinger et al.,
1999; Xie et al., 2008). This binding does not accelerate clear-
ance or degradation but rather begins a sustained period of
cellular activation mediated by receptor-dependent signaling,
leading to inflammation. It is proposed that RAGE activation is
largely responsible for the pathogenicity associated with AGEs
(Hofmann et al., 1999; Schmidt et al., 1995). Soluble RAGE
(sRAGE), a variant containing extracellular V, C1, and C2
domains serves as a scavenger and is a potent inhibitor of
RAGE signaling (Hori et al., 1995).
Other endogenous ligands are implicated in amplifying RAGE-
dependent proinflammatory signaling: cytokine-like mediators
of the S100 family (Hofmann et al., 1999) and amphoterin (Tagu-
chi et al., 2000), a nuclear protein released by necrotic cells.
Unlike AGEs and possibly amphoterin that bind to a single
domain, all three extracellular domains of RAGE are involved in
binding S100 proteins: S100A12 binds to the C1 domain (Xie
et al., 2007), S100B binds to V and C1 (Dattilo et al., 2007; Osten-
dorp et al., 2007), and S100A6 binds to V and C2 (Leclerc et al.,
2007). The differences between RAGE binding sites may
account for the diverse cellular responses caused by S100
proteins. Another major class of AGEs, imidazolones have also
been implicated as possible ligands of RAGE (Thornalley,
1998). The structural diversity of RAGE ligands and the fact
that RAGE recognizes a class of ligands, such as AGEs, led to
the hypothesis that RAGE is a pattern recognition receptor (Cha-
vakis et al., 2003).
Despite the fact that AGE-RAGE biology has been studied for
more than 20 years, very little is known about the structural
biology of AGE-RAGE complexes. This is mostly due to the
extensive heterogeneity of AGEs created by glycation reactions:
glycation reactions are not largely dependent on sequence
specificity, and lysine and arginine residues, which are particu-
larly susceptible to glycation, are very common in proteins. The
binding of AGE-modified proteins to the V domain of RAGE
depends weakly on either the primary or tertiary structure of
the AGE modified sites. And while individual CML (CEL) struc-
tures bind to the V domain of RAGE weakly, constitutive oligo-
merization of RAGE provides a mechanism for increasing the
number of binding sites and subsequently, the binding affinity
of AGEs (Thornalley, 1998; Xie et al., 2008).s reserved
Figure 1. CEL-Containing Peptides Can Be
Produced by Both Glycation and Chemical
Synthesis
(A) Fructosyllysine, CML, and CEL are the prod-
ucts of early and advanced glycoxidation of
sugars.
(B) Synthetic CEL-peptide, DEF(CEL)ADE,
contains a correct chemical structure of
N3-carboxy-ethyl-lysine. To characterize CEL-
peptide, we collected two 2D homonuclear NMR
experiments, 1H,1H TOCSY and 1H,1H ROESY.
The 1H,1H TOCSY strip shows through bond
correlation between the amide proton (8 ppm) and
side-chain protons Ha (4.1 ppm), Hb (1.7 ppm), Hg
(1.2 ppm), Hd (1.5 ppm), and H3 (2.85 ppm) of CEL.
The 1H,1H ROESY strip shows through space
correlations between H3 and carboxyethyl protons
CH(CH3)-COOH (3.8 ppm) and CH(CH3)-COOH
(1.7 ppm) of CEL, confirming the presence of
a proper chemical structure of N3-carboxy-ethyl-
lysine.
See also Figure S1.
Structure
AGE Recognition by RAGEManyAGEstructures arepresent inplasmaat very lowconcen-
trations and thus, are unlikely to contribute significantly to RAGE
signaling (Thornalley et al., 2003). At the same time,CMLandCEL
are major AGEs found in tissue and blood plasma and have been
established as ligands of RAGE (Schmidt et al., 1996; Thornalley
et al., 2003). Structural information is critical to understand the
mechanismsofRAGEsignaling and to designandoptimize effec-
tive therapeutic agents against RAGE-caused pathologies.
Here, we solved a solution structure of a CEL-containing
peptide V domain complex. Structure of the V domain is closely
homologous to the variable domain of an antibody. CEL peptide
binds to the surface formed by the C, F, and G strands. TheStructure 19, 722–732, May 11, 2011homologous surface in the variable
domain of an antibody is used for hetero-
dimerization. We showed that both the
CEL moiety and the peptide backbone
make specific contacts with the V domain
of RAGE. The structure suggests how
RAGE can bind a large variety of CEL
(CML)-modified proteins. Specific
binding of CML (CEL)-modified proteins
to RAGE suggests that the receptor func-
tions as a sensor of cellular stress.
RESULTS
A variety of extracellular proteins contain-
ing CML or CEL and possessing unre-
lated primary sequences bind to RAGE.
Surprisingly, free CML and CEL do not
bind to RAGE (Xie et al., 2008). Only
CML or CEL embedded in a peptidic
structure are capable of binding (Xie
et al., 2008). Thus, to structurally charac-
terize AGE-RAGE interactions, we
synthesized short peptides containing
CML and CEL (Figure 1B; see Figure S1available online). The amino acid sequences of the peptides
represent the primary glycation sites found in human serum
albumin, HSA, a major plasma protein.
The affinities of CML (CEL) peptides for the V domain were
estimated by monitoring changes in the native tryptophan fluo-
rescence of the V domain upon ligand binding. Unmodified
peptides, F(K)DLGEE and DEF(K)ADE, bind to the V domain
with low affinities, whereas the binding of modified peptides is
6- to 7-fold greater (Table 1; Figure S2). As expected, the fluo-
rescence titration indicated that the binding depends only
slightly on the primary sequence of the peptide and even less
so on the type of AGE modification. For example, the modifiedª2011 Elsevier Ltd All rights reserved 723
Table 1. Binding Affinities of the CML Peptides for the Wild-Type
and Mutants of V Domain
Peptide
Sequence
V Domain
Kd, mM
1
R98A
V Domain
Kd, mM
1
K52A
V Domain
Kd, mM
1
K52A, R98A
V Domain
Kd, mM
a
DEF(CML)ADE 97 ± 3 725 ± 17 528 ± 19 830 ± 27
DEF(CEL)ADE 104 ± 5 685 ± 26 560 ± 32 912 ± 42
DEFKADE 617 ± 24 — — —
F(CML)DLGEE 87 ± 5 — — —
F(CEL)DLGEE 93 ± 6 — — —
FKDLGEE 673 ± 38 — — —
aDissociation constant was obtained by fitting fluorescence titration data
with a single site binding isotherm.
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AGE Recognition by RAGEpeptides F(CML)DLGEE and DEF(CML)ADE bind with 97 and
87 mM affinity, respectively, and F(CEL)DLGEE and DEF(CEL)
ADE bind with 104 and 93 mM affinity, respectively. Overall, the
binding affinities for all of the modified peptides examined
were very similar to one another.
Since CML and CEL differ only by a methyl group (Figure 1;
Figure S1), we hypothesized that the CML and CEL peptides
bind to the samemolecular surface of the V domain. NMR chem-
ical shifts of backbone amide protons and nitrogens are exqui-
sitely sensitive to the changes in chemical environment induced
by ligand binding. These changes allowed us to identify amino
acid residues of the V domain that are affected by the binding
of either DEF(CML)ADE (CML-PEP) or DEF(CEL)ADE (CEL-
PEP) (Figures 2B and 2C; Figure S3). Titrating the peptides into
the V domain led to gradual changes in the chemical shift of
the residues Asn25, Lys52, Glu97, Arg98, Cys99, Ala101, and
Lys110. This set of residues was virtually the same for CML-
PEP and CEL-PEP suggesting that the V domain does not
discriminate between these species and the same interaction
surface is involved in CML and CEL binding.
To elucidate the chemical nature of the interaction between
the V domain of RAGE and CEL (CML)-containing proteins, we
studied the solution structure of the V domain (residues 23–
123 of the 356 residue RAGE) in complex with the 7 residue
CEL-PEP. The structured regions comprise residues 23–92 of
the V domain and 3–5 of CEL-PEP. Based on the constraints ob-
tained from NMR experiments, 25 structures with the lowest
target function values were superimposed (Figure 3; Table S1).
The solution structure of the V domain-CEL-PEP complex is
similar to that of the free V domain (Matsumoto et al., 2008)
and V domain within a VC1 construct (Koch et al., 2010). The
root mean square (rms) deviations between the solution struc-
ture of the complexed and free V domain (PDB code 2E5E) or
V domain within VC1 construct (PDB code 3CJJ) are 1.8 and
1.4 A˚ for the backbone and 2.6 and 1.9 A˚ for all heavy atoms in
of the ordered regions. The large loop between strands C’ and
D was poorly defined in the free V domain (Matsumoto et al.,
2008) and excluded from structural comparison.
The solution structure of the V domain (Figure 4A) closely
resembles the structure of conventional immunoglobulin
V-type domains. Secondary structure elements were labeled
following the immunoglobulin convention (Bork et al., 1994; Cho-
thia and Jones, 1997). The network of hydrogen bonds in the724 Structure 19, 722–732, May 11, 2011 ª2011 Elsevier Ltd All rightRAGE V domain is different from that of the immunoglobulin-
like domains found in cell adhesion receptor molecules, such
as ICAM and JAM, suggesting a different mode of action. The
closest structural analog is a variable domain of the IgG1
P20.1 FAB light chain (PDB code 2ZPK; Nogi et al., 2008) Figures
2C and 4A; Figure S4).
The V domain structure consists of seven strands connected
by six loops, to form two beta-sheets. The disulfide bond
between Cys38 and Cys99 links these sheets into a beta-sand-
wich structure. Two antiparallel beta strands, B and D, are
shorter than in the conventional, IgG1 P20.1 FAB V-type domain
(Bork et al., 1994) (Figure 2C). This arrangement allows loops BC
and C’D to be packed against the core of the protein rather than
protruding into the solvent. Loops BC andC’D contain the hyper-
variable CDR1 and CDR2 regions of the antibody that are
involved in antigen binding (Figure 2C; Figure S4). Two other
regions distinct from conventional immunoglobulin structures
are a helix between strands C’ and D and the apparent lack of
the hydrogen bonds necessary to form the C’’ strand conven-
tionally found in variable-type domains.
The electrostatic potential mapped onto themolecular surface
of the V domain is shown in Figure 4B. There is only one obvious
hydrophobic cavity close to the C terminus formed by Ile 30, Pro
87, Ala 88, Ile 91, Tyr 118 around loop A’B and loop EF. The elec-
trostatic surface potential of the V domain reveals that the
molecular surface is covered by positive charges. In particular,
there are two areas where positive charges are densely localized
to form a cationic center. The first one consists of Lys52, Arg98,
and Lys110 and is positioned on a relatively flat molecular
surface. IgG1 utilizes this area to form heterodimers between
light and heavy chain variable domains (Figure 4A; Figure S4).
The second area of positive charge consists of Lys43, Lys44
on loop BC, and Arg104 on loop FG. Conventional antibodies
utilize the latter surface for specific ligand binding (Bork et al.,
1994; Nogi et al., 2008).
The binding conformation of the CEL-PEP peptide backbone
is bent at CEL and forms a loop possibly due to steric hindrance
caused by the bulky CEL group (Figures 3 and 4). The CEL-PEP
binding site is small, spanning 180 A˚2 and sits on a positively
charged groove formed by the C, F, and G strands. Conventional
antibodies use this surface for heterodimerization (Figure 4A;
Figure S4). The binding site for CEL-PEP is relatively flat, which
probably reflects the lack of specificity for primary structure
observed in binding experiments.
The CELmoiety of CEL-PEPmakes themajority of intermolec-
ular contacts (Figure 4C; Table S2). CEL-PEP also contacts only
a limited number of residues in the V domain of RAGE (Figure 4C;
Table S2). Ionic interactions predominate CEL-PEP-V domain
interactions since an increase in ionic strength from 200 to
400 mM abolished CEL-PEP binding. We detected an extended
network of nOes confidently placing the negatively charged car-
boxyethyl head group of CEL into the groove formed by posi-
tively charged Lys52, Lys110, and Arg98 (Figure 4C; Table S2
and Figure S4C). The rest of CEL fits snugly into a groove formed
by the F and G strands, which may provide additional hydro-
phobic contacts. To further demonstrate that Lys52 and Arg98
play a major part in the binding of CML (CEL)-containing
peptides to the V domain, we made single R98A and K52A,
and double R98A, K52A mutants of the V domain. The bindings reserved
Figure 2. RAGE V Domain Does Not Discriminate between CML- and CEL-Containing Peptides
(A) Overlay of 15N-HSQC of free (black) and CML-PEP bound (red) V domain.
(B) Overlay of 15N-HSQC of free (black) and CEL-PEP bound (red) V domain.
(C) Sequence alignment of V domain and a V-type domain from a heavy chain antibody IgG1 P20.1. Amino acid residues involved in CML (CEL) binding are in red.
CDR1 and CDR2, the hypervariable regions of IgG1 P20.1, are in blue. Secondary structure elements are shown above the sequences.
See also Figure S3.
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AGE Recognition by RAGEaffinities of CML-PEP and CEL-PEP for the mutant V domains
are 5- to 10-fold weaker than for the wild-type V domain, and
comparable to that of unmodified PEP (Table 1; Figure S2).
The CEL moiety binds to the V domain in an extended confor-
mation that is longer than any of the amino acids side chains. As
a result, substituting a negatively charged side chain such as GluStructure 19,for CEL will lead to loss of binding. Importantly, the methyl group
of CEL is oriented away from the binding site suggesting that
this group does not contribute to the binding free energy. This
configuration of CEL would explain why CML, which lacks the
methyl group, has a very similar binding affinity and fits into
a very similar interaction surface. Consistent with our previous722–732, May 11, 2011 ª2011 Elsevier Ltd All rights reserved 725
Figure 3. Stereo View of the Overlay of 25
Lowest Energy CEL-PEP V Domain Back-
bone Traces (PDB code 2L7U)
N and C termini of the V domain and CEL-PEP are
indicated. Figure is prepared by using Molmol
(Koradi et al., 1996). See also Table S1.
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AGE Recognition by RAGEbinding experiments, an early glycation end product, fructosylly-
sine (Figure 1A), which possesses a bulky head group, will not fit
into the CEL binding site on the V domain (Xie et al., 2008).
Our earlier observations suggest that interactions between the
CEL moiety and V domain are not sufficient to provide stable
binding since neither free CEL nor CML stably bind to the V
domain (Xie et al., 2008).We hypothesized that the peptide back-
bone conformation is important for CEL-PEP binding to the V
domain. Indeed the backbone amide proton of CEL-PEP Ala5
is located within 2.5 A˚ of the V domain Asn112 side-chain
carbonyl group and possesses geometry consistent with
a hydrogen bond (Figure 4C). The chemical shift of the Ala5
amide proton exhibits a downfield shift from 7.6 to 8.2 ppm
upon CEL-PEP binding to the V domain, which is also indicative
of hydrogen bond formation. We detected intermolecular
contacts between Hb of the Ala5 side chain and Hd of Arg114,
which may strengthen the CEL-PEP peptide backbone-V
domain interaction (Table S2 and Figure S4C). Additional hydro-
phobic contacts are supplied by V domain residues Trp61, Ile96,
and Phe97, which together extend the hydrophobic surface
along face of Phe3, since we detected an intermolecular nOe
between Hb of Phe3 and Hd of Ile96 (Figure S4C). At the same
time, the interaction between the benzene ring of Phe3 and the
V domain is not specific since we did not identify an extensive
network of nOes from the V domain to Phe3 benzene ring (Fig-
ure 4C; Table S2). The side chain of Phe3 is not well defined in
the V domain-CEL-PEP complex (Figure S4D). In addition, during
the CEL-PEP-V domain titration residues Trp61, Ile96, and
Phe97 did not undergo the large chemical shift changes ex-
pected for ring current shifts (Perkins and Wuthrich, 1979). This
hydrophobic surface is large enough to accommodate any
side chain, possibly providing an increase in binding affinity
without a subsequent increase in specificity.
To rationalize the ability of RAGE to bind various CML- and
CEL-modified proteins, we structurally aligned CEL-PEP with
three-dimensional structures of loops from BSA reported to
contain major glycation sites (Wa et al., 2007; Figure 4D). Three
out of six loops possessed conformations that are compatible
with binding to the V domain. Importantly, the conformation of
the backbone amide group that follows the AGE-modified lysines
in these loops are almost identical to that of CEL-PEP. Moreover,
it is known that glycation disrupts local secondary structure
rendering the area immediately around the modified site726 Structure 19, 722–732, May 11, 2011 ª2011 Elsevier Ltd All rights reservedextremely flexible (Povey et al., 2008).
This suggests that evenCML (CEL)-modi-
fied sites, which do not initially possess
proper binding geometry, may be able to
bind to the V domain by using induced fit.
Soluble RAGE (sRAGE) works as
a scavenger to remove ligands capableof activating RAGE expressing cells (Hofmann et al., 1999). We
used this function of sRAGE to test whether our structure of
the CEL-PEP-V domain reflects physiological interactions
between RAGE and CML modified proteins. Instead of the
V domain that binds to CML peptides only weakly, we used
the VC1 domain of RAGE that dimerizes (Xie et al., 2007; Koch
et al., 2010; Zong et al., 2010) (Figure 5A; Figure S5A) and
thus, is capable of binding multiple CMLs with increased binding
affinity. CML-modified BSA was used as a RAGE activating
ligand. To interrogate the functional implications of these find-
ings, we used two RAGE-expressing cell types, C6 glioma cells
and primary murine aortic vascular smooth muscle cells (VSMC)
(Brett et al., 1993; Taguchi et al., 2000). Cellular activation was
monitored by observing the increase in phosphorylation levels
of two key signal transduction proteins previously shown to be
downstream of RAGE: ERK and P38 (MAPK)(Kislinger et al.,
1999).
Wild-type VC1 inhibited CML-BSA induced RAGE signaling in
both C6 glioma and VSMC cells, as evidenced by no increase in
the levels of phosphorylated ERK (pERK) and phosphorylated
MAPK (pP38) relative to the control lane (Figures 5B and 5C;
Figures S5B and S5C). Total ERK and P38 MAPK levels re-
mained constant for all experiments. The two single mutants,
R98A and K52A, and one double mutant of VC1, R98A, K52A
(KRA), failed to inhibit RAGE signaling induced by CML-BSA,
strongly suggesting that the identified CEL (CML) binding site
is critical for the CML-BSA induced activation of RAGE.
DISCUSSION
The structure of the V domain with its physiological ligand, CEL-
PEP, reveals how RAGE is able to recognize CML (CEL)-modi-
fied proteins when the modification site can possess very
different primary, secondary, and tertiary structures. The
V domain of RAGE makes molecular contacts with both the
CEL (CML) moiety and the peptide backbone in the immediate
vicinity of CEL (CML). The V domain does not discriminate
between CEL and CML. The negative charge of CEL (CML) is
a critical determinant for binding to the positively charged
V domain surface. The extended geometry of CEL (CML) and
the distance from the negative carboxyl group to the peptide
backbone is also critical for molecular recognition. These two
conditions will preclude binding of either negatively charged
Figure 4. Solution Structure of the CEL-PEP-V Domain Complex
(A) Structure of CEL-PEP bound to V domain. V domain is shown in ribbon representation. Elements of secondary structure are labeled following the immu-
noglobulin convention (Bork et al., 1994).
(B) Electrostatic potential is mapped onto the molecular surface of the V domain. Positively and negatively charged surfaces are indicated in blue and red,
respectively.
(C) V domain amino acid residues located within 5 A˚ from the CEL moiety of CEL-PEP. Putative hydrogen bond between the backbone amide proton of Ala5 and
the side-chain carbonyl group of Asn112 is indicated. Carbon atoms of CEL-PEP and V domain are in yellow and cyan, respectively.
(D) Structural alignment of CEL-PEP with three short segments from human serum albumin (HSA)-containing lysines (Wa et al., 2007), 11-FKD, 56-AKT, and 261-
AKY. The lysines in these sequences were shown to be glycated under elevated concentrations of D-glucose.
See also Figure S4 and Table S2.
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AGE Recognition by RAGEamino acids or bulky early glycation products, such as fructosyl-
lysine, to the CEL-PEP binding site. The torsional angles of the
CEL-PEP peptide backbone when bound to the V domain, allow
different sequences within the AGE-modified protein to fit into
the binding site. The latter explains why RAGE can bind to
various CML (CEL)-modified proteins found in tissue and in
plasma.
Binding of CEL-PEP to the V domain is clearly specific. Is the
binding of CML (CEL) proteins to RAGE physiologically impor-
tant and how does it relate to the immune response caused by
RAGE signaling? CML and CEL-modified proteins are found
under normal physiology (Thornalley et al., 2003). However,
their concentration is low and individual proteins have atStructure 19,most only a single CML (CEL)-modified lysine. Since binding
of a single CML peptide to the V domain is weak this event
will not trigger RAGE signaling (Xie et al., 2008). Under cellular
stress, caused by different pathologies including diabetes, Alz-
heimer’s disease, or cancer, the concentration of CML (CEL)
proteins increases, thus increasing the amount of multiple-
modified proteins (Brownlee, 1995). Since RAGE is a constitu-
tive oligomer (Xie et al., 2007; Koch et al., 2010; Zong et al.,
2010), polyvalent engagement of CML proteins and RAGE
results in tight binding, thus, triggering the RAGE-dependent
immune response. This mechanism suggests a physiological
role for RAGE as a sensor of cellular stress caused by various
pathologies (Schmidt et al., 2000). It also highlights an722–732, May 11, 2011 ª2011 Elsevier Ltd All rights reserved 727
Figure 5. Mutants of the VC1 Domains of
RAGE Fail to Suppress CML-BSA-Induced
RAGE Signaling
(A) Cartoon model of how RAGE dimerization
promotes V domain binding to multiple CML
moieties on CML-BSA (ribbon). The molecular
surface of the V domain involved in CML(CEL)
binding is in red. Only two V domains are shown.
Lysines of BSA, which may undergo glycation are
in yellow. The cartoon model was prepared by
using SWISS-PDB Viewer (Guex and Peitsch,
1997).
(B and C) Single K52A and R98A, and double
K52A, R98A (KRA) mutants of the VC1 domains do
not interfere with CML-BSA induced RAGE
signaling in both C6 rat glioma (B) and mouse
VSMC cells (C).
See also Figure S5.
Structure
AGE Recognition by RAGEopportunity to interfere with RAGE signaling by obstructing low
affinity ligand binding. The structure of the CML-PEP-V domain
will rationalize these efforts.
EXPERIMENTAL PROCEDURES
Reagents and Chemicals
Restriction enzymes and Taq polymerase were from NEB. All other chemicals
used were reagent grade or better.
Solid-Phase CML Peptide Synthesis
CML- and CEL-containing peptides were synthesized on a multiple synthe-
sizer SYRO2000 (MultiSynTech GmbH, Witten, Germany) by using 9-fluore-
nylmethoxycarbonyl/tert-butyl (Fmoc/tBu)-chemistry on Wang resin (Atherton
et al., 1978) utilizing a global postsynthetic alkylation approach. The side728 Structure 19, 722–732, May 11, 2011 ª2011 Elsevier Ltd All rights reservedchains of Asp and Glu were protected with tBu
and the side chain of Lys with 4-methyltrityl
(Mtt). Fmoc-amino acid derivatives were acti-
vated with N,N’-diisopropylcarbodiimide (DIC)
and N-hydroxy-benzotriazole (HOBt) at equimolar
ratios, added to the resin with eight molar
excess, and reacted at room temperature for
70 min. After completion of the synthesis, the
Fmoc group was cleaved with piperidine and
the free N terminus was protected again with
a mixture of di-tert-butyl dicarbonate (Boc2O,
20 eq) and N,N-diisopropylethylamine (DIPEA,
10 eq) in N,N-dimethylformamide (DMF) at room
temperature overnight. The Mtt group was
cleaved with 2% (v/v) trifluoroacetic acid (TFA)
and 1% (v/v) triisopropylsilane (TIS) in dichloro-
methane (DCM) two times for 30 min. The resin
was washed three times with DCM and dried
before the unprotected 3-amino groups of the
lysine residues were alkylated with 2-chlorotrityl
3-bromopropanoate (or 2-chlorotrityl bromoace-
tate) (20 eq) in the presence of DIPEA (10 eq) in
DCM to obtain the protected CEL (or CML)
peptides, respectively. Peptides were cleaved
with TFA containing 12.5% (v:v) of a scavenger
mixture (ethanedithiole, m-cresole, thioanisole
and water, 1:2:2:2) at room temperature for
2 hr. The peptides were precipitated with cold di-
ethyl ether and purified by RP-HPLC by using
a linear aqueous acetonitrile gradient (5 mmol
ammonium formate [pH 3.2]) as ion pair reagenton a Jupiter C18-column (21.2 mm internal diameter, 250 mm length,
15 mm particle size, 30 nm pore size) (Phenomenex Inc., Torrance, CA).
The purities of the peptides were confirmed by RP-HPLC and the molecular
weight by matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF-MS; 4700 proteomic analyzer; Applied Biosys-
tems GmbH, Darmstadt, Germany) using an a-cyano-4-hydroxycinnamic
acid matrix.
Preparation of 2-Chloro-Trityl 3-Bromopropanoate
and 2-Chloro-Trityl 3-Bromoacetate
3-Bromopropionic acid (9.6 mmol, 0.86 ml) or bromoacetic acid (9.6 mmol,
3.0 g) were mixed with equimolar amounts of 2-chlorotrityl chloride (1.34 g)
and DIPEA (1.65 ml) in dichloromethane (25 ml). This mixture was stirred at
room temperature for 1 hr before the solvent was removed on a rotary evapo-
rator. The dry products were used without further purification to alkylate the
side chains of lysine residues.
Structure
AGE Recognition by RAGEPlasmid Construction
Human RAGE cDNA library clone BC020669 was obtained from Open Biosys-
tems and used as a template for PCR amplifications. DNA coding for the
V domain (amino acids 24–125) was PCR-amplified using Taq polymerase
and oligonucleotides 50-TTTCATATGGCTCAAAACATCACAGCCCGGATTGG
and 30-TTTGTCGACTCATTCTGGCTTCCCAGGAATCTG containing flanking
50-NdeI and 30-SalI restriction sites. The restriction-digested PCR products
were ligated into expression vector pET28a (Novagen), which confers kana-
mycin resistance. The resulting plasmid, pET28-V, expresses a C-terminal
His-tagged V domain of RAGE. DNA coding for VC1 fragments (amino acids
23–243) were PCR amplified using oligonucleotides 50-TTTCATATGGCT
CAAAACATCACAGCCCGGATTGG and 30-TTTGAGCTCCACCACCAATTG
GACCTCCTCCAG containing 50-NdeI and 30-XhoI restriction sites. DNA frag-
ments were subcloned into the NdeI and XhoI sites of pET15b vector (Nova-
gen), which confers ampicillin resistance. The resulting plasmid, pET15b-
VC1, expresses an N-terminal His-tagged VC1 domain.
Labeling, Expression, and Purification of Wild-Type and Mutant
V Domains
To uniformly label the V domain of RAGE, pET28-V, pET28-R98A-V, pET28-
K52A-V, or pET28-K52A-R98A-V were transformed into Escherichia coli strain
BL21(DE3) Codon+ (Novagen). For U-15N labeling, cells were grown at 37C in
minimal medium (M9) containing 35 mg/liter kanamycin and 1 g/liter [15N]
ammonium chloride as the sole nitrogen source. For U-13C,15N labeling, cells
were grown at 37C in M9 medium containing 35 mg/liter kanamycin, 1 g/liter
[15N]ammonium chloride, and 2 g/liter [13C]glucose instead of unlabeled
glucose as the sole carbon source. Cells were grown to 0.7 OD600 at 37
C,
induced with 0.5 mM isopropyl 1-thio-b-d-galactopyranoside (IPTG), and
grown overnight. Cells were harvested and resuspended in 20 mM HEPES-
Na [pH 7.0] buffer, containing 8 M urea and heat lysed at 100C for 10 min.
The lysate was centrifuged, and the supernatant was loaded onto a nickel-
nitrilotri-acetic acid-agarose (Ni-NTA) column (QIAGEN). The column was
washed with 20 mM HEPES-Na buffer (pH 7.0) and the protein was allowed
to renature on the column before eluting with 20 mMHEPES-Na (pH 7.0), con-
taining 500mM imidazole. Fractions containing the eluted protein were pooled
and dialyzed into NMR buffer (10 mm sodium phosphate [pH 6.5], 100 mM
NaCl, 0.02% (w/v) NaN3). The C-terminal His tag of the V domain was cleaved
by thrombin (Novagen) at room temperature for 1 hr before gel filtration chro-
matography on a SE-75 column (Amersham Biosciences). The fractions con-
taining the eluted protein were concentrated by using Ultra-Centricones (Milli-
pore). Purity was estimated to be >95% by Coomassie-stained SDS-PAGE.
Expression and Purification of Wild-Type and Mutant VC1 Domains
RAGE fragments were overexpressed in E. coli strain OrigamiB-(DE3) (Nova-
gen), grown at 37C to OD600 0.8, adjusted to 20C for 30 min, induced
with 1 mM IPTG, and allowed to express for 4–6 hr. Cells were lysed at 4C
in lysis buffer (20 mM Tris-HCl [pH 8.0], 20 mM imidazole, 300 mM NaCl) in
the presence of lysozyme (5 mg/ml), followed by sonication (5 min with
a 50% duty cycle). Clarified lysate was initially purified on a Ni-NTA (QIAGEN)
column equilibrated with lysis buffer and eluted with 20 mM Tris-HCl [pH 8.0],
100 mM imidazole, 300 mM NaCl. The C-terminal His tag of the VC1 domain
was cleaved by thrombin (Novagen) at room temperature for 1 hr before gel
filtration chromatography on a SE-75 column (Amersham Biosciences). The
fractions containing the eluted protein were concentrated by using Amicon-
Ultra-Centricones (Millipore). Residual endotoxin was removed from the
sample by repetitive use of EndoTrap Red (Lonza). The endotoxin level of
the final protein solution was determined by using Gel Clot LAL Assay (Lonza)
to be less than 0.1 EU/ml. Purity was estimated to be >95% by Coomassie-
stained SDS-PAGE.
Preparation of CML-Bovine Serum Albumin
We followed the protocol (Kislinger et al., 1999) that leads exclusively to CML
modifications of lysine. In brief, CML-BSA was prepared by incubating 5 mM
BSA (fraction V, fatty acid free, endotoxin free bovine serum albumin, EMD) in
150 mM sodium phosphate buffer [pH 7.4], containing 25 mM glyoxylic acid
and 75 mM NaBH3CN, at 50
C for 48 hr. The reaction mixture was dialyzed
against 10 mM sodium phosphate buffer [pH 7.0] and 100 mMNaCl to remove
unreacted glyoxylic acid and NaBH3CN and stored at 20C in 20% glycerol.Structure 19,The extent of chemical modification was determined colorimetrically by using
2,4,6-trinitrobenzenesulfonic acid to measure the difference spectrum
between lysine residues of modified and unmodified protein preparations
(Habeeb, 1966). The extent of lysine modification of CML-BSA preparations
was 21%.
Site-Directed Mutagenesis of the V and VC1 Domains
To singly or doubly mutate the V domain of RAGE, the QuikChange II XL Site-
Directed Mutagenesis Kit (Strategene) was used. Following mutagenic PCR,
pET28-V was restriction digested with DpnI for 1 hr and transformed into
E. coli strain DH10B. Mutated plasmids were isolated and purified using
Mini-Prep Kit (QIAGEN). DNA sequencing identified plasmids pET28-R98A-
V, pET28-K52A-V, or pET28-K52A-R98A-V, which code for the appropriate
mutant V domain.
To singly or doubly mutate the VC1 domain of RAGE, High-Fidelity DNA
polymerase (New England BioLabs) was used. Following mutagenic PCR,
pET15-VC1 was transformed into E. coli strain XL-1 Blue. Mutated plasmids
were isolated and purified using a Mini-Prep Kit (QIAGEN). DNA sequencing
identified plasmids pET15-R98A-VC1, pET15-K52A-VC1, and pET15-K52A-
R98A-VC1, which code for the appropriate mutant VC1 domain.
NMR Experiments
CEL- and CML-containing peptides were assigned using 2D 1H,1H TOCSY
and 1H,1H ROESY experiments (Cavanagh et al., 1996), which provide through
bond and through space proton connectivities. Protein samples of the
uniformly labeled, [U-13C,15N] and [U-15N], V domain, with concentrations
ranging from 60 to 300 mM were dissolved in NMR buffer (10 mM potassium
phosphate [pH 6.5], 100 mM NaCl, 0.02% (w/v) NaN3, in 90%H2O/10%D2O)
and unlabeled peptide, CEL-PEP or CML-PEP, was added to a 1.2 molar
excess. To obtain backbone resonance assignments of the [U-13C,15N]
V domain-CEL-PEP complex, standard triple resonance spectra 1H,15N
HSQC, HN(CA)CO, HNCO, HN(CO)CA, HNCA, CBCA(CO)NH, and HNCACB
(Cavanagh et al., 1996) were acquired at 298 K using an Avance Bruker spec-
trometer operating at a 1H frequency of 700MHz equipped with a single Z-axis
gradient cryoprobe. To obtain the side-chain resonance assignments of
V domain bound to CEL-PEP, 1H, 13C HSQC, 1H, 13C 3D NOESY-HSQC,
and 3D HCCH-TOCSY experiments (Cavanagh et al., 1996) were performed.
To assign intramolecular nOes in CEL-PEP, a 15N-filtered 13C filtered
NOESY-HSQC (Cavanagh et al., 1996; Iwahara et al., 2001; Zwahlen et al.,
1997) was acquired on an NMR sample containing 300 mM [U-13C,15N]
V domain and 200 mM unlabeled CEL-PEP, and a 13C-double-filtered
NOESY-HSQC (Cavanagh et al., 1996; Iwahara et al., 2001; Zwahlen et al.,
1997) was acquired on a NMR sample with 350 mM [U-13C,15N] V domain
and 200 mM unlabeled CEL-PEP. To assign intermolecular nOes, a 15N-edited
13C filtered NOESY-HSQC (Iwahara et al., 2001; Zwahlen et al., 1997) was
acquired on an NMR sample containing 320 mM [U-13C,15N] V domain and
1 mM unlabeled CEL-PEP, and a 13C-edited, 13C filtered NOESY-HSQC
(Iwahara et al., 2001; Zwahlen et al., 1997) was acquired on the NMR sample
with 300 mM [U-13C,15N] V domain and 1 mM unlabeled CEL-PEP. To identify
the peaks from intramolecular 13C-bound protons, the NOESY spectra were
acquired both with and without heteronuclear 13C decoupling during the
indirect proton acquisition period. Peaks that were split in the absence of
decoupling were assigned to intramolecular V domain nOes. All spectra
were processed using TOPSPIN 2.1 (Bruker, Inc), and assignments were
made using CARA (Masse and Keller, 2005).
To obtain translational diffusion coefficients, D, gradient diffusion experi-
ments were performed using the pulse sequence described by Ferrage et al.
(2003).A 100 mMprotein sample of the uniformly labeled [U-15N] VC1 construct
was dissolved in NMR buffer (10 mM potassium phosphate [pH 7.2], 100 mM
NaCl, 0.02% (w/v) NaN3, in 90%H2O/10%D2O). The attenuation of the NMR
signal due to the increase in the strength of the gradient field was used to
calculate translational diffusion coefficients that, for a spherical Brownian
particle, is inversely proportional to the Stokes’ radius (Schimmel and Cantor,
1980),
D=KBT=ð6phraÞ; (1)
with KBT being the thermal energy, h the viscosity of the solvent and ra the
Stokes’ radius. In our experiment, the diffusion delay was D+ 6t =1 s; each722–732, May 11, 2011 ª2011 Elsevier Ltd All rights reserved 729
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ficients were calculated by fitting integrated amide signal intensities using the
equation:
S=S0 = exp
 Dk2ðD+ 6tÞ; (2)
where
k=gsGmaxd: (3)
g is the proton gyromagnetic ratio, s the shape of the encoding and decoding
gradient pulses, and G their peak amplitude.
Structure Calculation
Structural calculations were carried out with Cyana 2.1(Guntert, 2004)
using 986 distance restraints derived from 13C-edited NOESY and 15N-edited
NOESY spectra, 150 backbone torsion angle restraints derived from TALOS
(Cornilescu et al., 1999), 38 restraints for hydrogen bonds, and the restraints
from one disululfide bond between Cys38 and Cys99. nOes were converted
to upper limit distances using the CALIBA module in CYANA (Guntert, 2004).
The reference volume determined by CALIBA was increased two times before
conversion in order to loosen the distance restraints. All upper limit distances
for intermolecular nOeswere set to 6 A˚. The geometry of unnatural amino acids
CML and CEL were added to the CYANA library. Backbone torsion angle
restraints for CEL-PEP were estimated by using TALOS (Cornilescu et al.,
1999). These experimental restraints are summarized in Table S1. To perform
CYANA calculations, a single polypeptide chain was constructed for the V
domain and CEL-PEP molecules.
Refinement
The CYANA-generated distance and angle restraints were converted into CNS
format in CCPN (Fogh et al., 2002). The structure for the nonstandard amino
acids CEL and CML was generated and energy-minimized in PRODRG2
(Schuttelkopf and van Aalten, 2004). A total of 1000 structures were calcu-
lated, and the 200 lowest energy structures were subjected to water refine-
ment and further analysis by PROCHECK_NMR (Laskowski et al., 1996).
80.5% of the V domain residues were in the most favorable regions of Rama-
chandran plot, 18.2% were in the additional allowed regions and 1.3%were in
generously allowed regions. There were no residues in the disallowed regions
of the Ramachandran plot. The structural statistics of the 25 best structures
are reported in Table S1.
Fluorescence Titration
Measurements were performed on a Fluorolog-3 fluorescence spectropho-
tometer (HORIBA Jobin Yvon) at 25C in a 1 ml stirred cuvette. For fluores-
cence titration experiments, 100 nM of V domain dissolved in 10 mM phos-
phate buffer [pH 6.5] and 100 mM NaCl was used, and 1 mM solution of
CML- and CEL-containing peptides was used to increase the concentration
in 10 nM steps. Titrations in the absence of V domain and in the absence
CML (CEL) peptides were performed as references. Tryptophan fluorescence
was measured using an excitation wavelength of 280 nm. The fluorescence
emission signal was subtracted from the signal of the reference titrations,
and the differences adjusted by the dilution factor were plotted against the final
concentration of added CML (CEL) peptide. Curve fitting (OriginLab) was per-
formed to find the best values for Kd using a single site binding isotherm
approximation (Eftink, 1997).
Cell Lines and Materials
Wild-type mice primary vascular smooth muscle cells were isolated and
cultured from aortas and employed through passage 5 to 7. Rat C6 glioma
cells were obtained from ATCC (CCL-107) and maintained in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum (Invitro-
gen). Primary vascular smooth muscle cells and C6 glioma cells were seeded
at 1 3 106 cells/100 mm dish in complete medium and grown for 24 hr before
starvation overnight in serum-free medium. After overnight starvation cells
were stimulated with 10 mg/ml CML-BSA or preincubated (2 hr at 4C)
CML-BSA with at least equimolar amounts of single mutants K52A, R98A,
double mutant K52A-R98A, or wild-type VC1 domain for the indicated time
point, rinsed with ice-cold phosphate-buffered saline, and lysed using lysis730 Structure 19, 722–732, May 11, 2011 ª2011 Elsevier Ltd All rightbuffer (Cell Signaling Technology) containing 1 mM phenylmethylsulfonyl fluo-
ride and Complete Protease Inhibitors (Roche Applied Science).
Western Blot Analysis
Total cell lysate was immunoblotted and probed with ERK, p-ERK, P38, and
pP38 specific antibodies (Cell Signaling Technology), HRP-conjugated donkey
anti-rabbit IgG (Amersham Pharmacia) or HRP-conjugated sheep anti-mouse
IgG (Amersham Pharmacia) were used to visualize the bands on the gel. After
probing with the p-ERK and pP38 antibodies, membranes were stripped of
bound immunoglobulins and reprobedwithERKorP38antibody for relative total
protein. Blots were scannedwith an AlfaImager TM 2200 scanner with AlfaEase
(AlfaImager) FC 2200 software. Results are reported as a relative of test antigen
to relative total proteins. In all western blot studies, at least three cell lysates per
group were used; results of representative experiments are shown.ACCESSION NUMBERS
Coordinates and chemical shift assignments of the CEL-PEP V domain
complex have been deposited in the Protein Data Bankwith accession number
2L7U.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and two tables and can be
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